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Summary
extramedullaryplasmacytoma (eMp) represents a 
peculiar and typically progressive malignancy that can 
originate outside the bone marrow. primary pulmonary 
plasmacytoma (ppp) is a rare subset of eMp, confined 
to the lung. a 55-year-old man, diabetic, non-smoker 
presented to our clinic with a right chest wall swelling. 
a routine chest radiograph showed a well-circumscribed 
opacity in the right upper lung zone. a Ct of the chest 
revealed a large right upper lobe mass with extensive 
local infiltration. Biopsy and immunohistochemical 
evaluation led to a diagnosis of ppp. screening for 
multiple myeloma was negative. serum immunofixation 
showed an IgG lambda monoclonal gammopathy, found 
in a minority of ppp patients. In view of disease extent, 
treatment with chemotherapy and radiotherapy was 
initiated. the patient is currently in out patient follow-up 
and has shown a favourable response to the treatment 
with a considerable decrease in serum IgG levels.
BaCkground
Plasma cell neoplasms can present as solitary (soli-
tary plasmacytoma) or multiple lesions (multiple 
myeloma, MM). Solitary plasmacytomas occur 
most frequently in bone but on occasion they can 
also be found in soft tissues, termed extramedullary 
plasmacytomas (EMP).1 EMP constitutes 3%–5% 
of plasma cell tumours with a predilection for the 
upper aerodigestive tract.2–4 A primary pulmonary 
origin is an exceedingly rare occurrence, with a 
varied and non-specific clinical and radiological 
expression, presenting a diagnostic challenge to 
the clinician. By definition, patients with primary 
pulmonary plasmacytoma (PPP) do not develop 
osteolytic bone lesions, hypercalcaemia or renal 
failure. Serum M-proteins are seen in a minority of 
the cases with PPP, with a predominance of IgG, 
Kappa (k) light chains.5 Guidelines on the manage-
ment of EMP refer mainly to tumours located in 
the head and neck, these cannot be strictly applied 
to patients with PPP.6 Data regarding prognosis and 
risk of progression to MM is scant, rendering the 
long-term follow-up of such patients crucial.7 Here, 
we report a case of PPP with IgG lambda mono-
clonal gammopathy, followed by a brief review of 
the literature.
CaSe preSenTaTion
A 55-year-old man, diabetic with no smoking history 
presented to us with pain, redness and swelling of his 
right upper anterior chest. There was an associated 
history of shortness of breath, backache, progres-
sive generalised weakness and weight-loss over a 
6 month period. Physical examination revealed a 
firm, non-tender swelling on the right side of his 
sternum (figure 1). On auscultation, breath sounds 
were not audible in the posterior upper chest. Clin-
ical examination of the remaining organs and appa-
ratuses was otherwise unremarkable.
inveSTigaTionS
Laboratory investigations showed normal complete 
blood counts with haemoglobin 120 g/L  , leuco-
cyte count of  4.7×109/L with 51.2% neutrophils, 
34.2% lymphocytes, and 11.8% monocytes and 
platelet count  205×109/L. Blood chemistry values 
were all within normal limits, with a creatinine of 
0.9 mg/dL.
Chest radiograph showed a well-demarcated 
homogenous opacity in the right upper lung zone 
(figure 2). At this point, there was a high suspi-
cion of a primary pulmonary malignancy and a CT 
scan of the chest was ordered to confirm or refute 
this suspicion. The CT scan showed a right upper 
lobe lobulated mass, 10.2×8.8×11.2 cm in size, 
anteriorly eroding the sternum and adjacent first 
rib, superiorly extending into the supraclavicular 
region with infiltration of the sternocleidomastoid, 
medially abutting the mediastinal vessels and supe-
rior vena cava with infiltration of the T1 vertebra 
and extension into the neural foramina at the T1-2 
level with enlarged right hilar and pre-carinal 
lymph nodes (figure 3A,B). A CT-guided percuta-
neous needle aspiration biopsy of the mass showed 
linear cores of tissue exhibiting diffuse dense 
infiltration by plasmacytoid cells with moderate 
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immunoreactive to MUM-1, CD138 and CD56 indicating a 
plasmacytoma (figure 4A–D). Serum immunofixation showed 
IgG lambda monoclonal gammopathy. Serum IgG, IgA and 
IgM levels were 70.47 g/L, 1.26 g/L and 0.66 g/L, respectively. 
Further work-up revealed normal levels of serum albumin, 
calcium, lactate dehydrogenase and uric acid. Serum B2 micro-
globulin level was 3551 ng/mL. Further screening for MM with 
bone marrow biopsy and skeletal survey was negative. Concur-
rent cytogenetic and fluorescence in situ hybridization studies 
disclosed a normal karyotype with no aberrations.
TreaTmenT
The patient was managed as a case of PPP with IgG lambda 
monoclonal gammopathy.
Taking into account, the size of the primary lesion along 
with extensive local infiltration, making complete surgical 
excision difficult, we planned radiotherapy and six cycles of 
chemotherapy, namely cyclophosphamide, bortezomib and 
dexamethasone.
ouTCome and Follow-up
The patient showed notable clinical improvement with reduc-
tion in IgG levels from 70.47 g/L at presentation to 57.37 g/L, 
48.39 g/L, 15.13 g/L and 12.02 g/L at 4, 8, 20 and 24 weeks of 
treatment, respectively, and a significant reduction in primary 
tumour size at 6 months follow-up.
Patients with PPP constitute a high-risk population for devel-
oping MM, warranting close follow-up. Our patient is being 
followed closely for any untoward outcomes.
diSCuSSion
EMP, are rare plasma cell tumours that arise outside the bone 
marrow, constituting 3% of the plasma cell malignancies.2 3 
Eighty per cent of the cases involve the upper respiratory tract. 
Less frequent sites of involvement include the gastrointestinal 
tract, liver, lymph nodes, testis, skin and central nervous system.4
PPP are rare EMP located in the lung. In a review of 36 
published cases of PPP, Stuppi et al reported a mean and median 
age of 57 and 58 years, respectively, consistent with prior 
reviews.5 Contrary to EMP of other sites a fairly even ratio of 
1.3:1 was noted between men and women.8
The clinical manifestations of PPP are closely related to the 
tumour location and are variable. Accurate radiographic diag-
nosis is extremely difficult. Cumulative reports indicate that 
radiographic findings with PPP tend to be non-specific, with 
two patterns of growth observed: nodule/mass, with upper lobe 
predominance9 or pulmonary infiltrates10 with or without local 
lymph node involvement. Rarely, pleural involvement has also 
been reported.11 However, these findings are not specific and 
can also be seen in more common tumours including lung carci-
noma, metastatic tumours, tuberculoma and hamartoma. Our 
patient presented with vague respiratory symptoms accompa-
nied by pain, redness and swelling of the right anterior chest 
wall. Radiographically, the lesion was rounded, homogenous in 
density, with lobulated margins.
Based on a literature review of 19 previously published cases 
of PPP by Joseph et al, the presence of neoplastic cells in sputum 
cytology and bronchoscopy were noted to carry a poor diag-
nostic yield. Fine-needle aspiration or thoracotomy was often 
required for a definitive diagnosis.12
MM can also involve the lung and in order to differentiate 
it from PPP a systemic staging system including skeletal survey, 
bone marrow examination and immunoelectrophoresis of serum 
and urine are required to rule out systemic disease.13 Unlike MM, 
PPP can lack an associated M-protein in the serum or Bence-
Jones light chains in urine. Their presence is however directly 
related to the tumour cell mass. Some speculate that the smaller 
tumour burden in EMP could explain the lower frequency of 
detection of M-proteins in the disease.14 15 The development or 
disappearance of an M-protein and the magnitude of the M-pro-
tein level was seen to mirror tumour burden and hence clinical 
course. Koss et al reported IgG as the predominant M-protein 
with kappa (k) light chain in a review of five cases of PPP.5 To our 
knowledge, three other cases of PPP with IgG, lambda mono-
clonal gammopathy have been reported in literature.9 16 17
Figure 2 Chest X-ray showing right apical pulmonary opacity.
Figure 3 (A) CT scan of the chest (axial view) revealing right apical 
lobulated mass, 10.2×8.8×11.2 cm in size, anteriorly eroding the 
sternum and adjacent first rib. (B) CT scan of the chest (axial view) 
revealing right apical lobulated mass medially extending to the 
mediastinum and abutting the mediastinal vessels and superior vena 
cava.
Figure 4 (A)H&E stain (40×10) showing neoplastic plasma cells with 
pleomorphism (arrow) (B): Immunohistochemical (IHC) stain with MUM 
1 protein, showing nuclear positivity in plasma cells (40×10) (C): IHC 
stain with CD56 showing membranous positivity in neoplastic plasma 
cells (40×10) (D): IHC stain with CD138 showing membranous positivity 
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There are no standard guidelines for the management of PPP, 
due to limited follow-up data on too few patients. Solitary PPP 
are best treated with anatomic pulmonary resection with or 
without radiotherapy.18 Joseph et al reported that radiotherapy 
and surgery carried an equal efficacy as treatment modalities.9 
Adjuvant chemotherapy seems to have no particular benefit on 
control or progression to MM,3 and it is usually reserved for 
patients with diffuse disease, aggressive histological forms and 
as a therapeutic alternative for patients with inoperable disease 
or poor local control after surgery or radiotherapy.19 20 Nie et 
al reviewed one case of multiple lung nodules, three cases of 
diffuse pulmonary infiltration and one case of a tumour in each 
lung treated with combination chemotherapy, namely melphalan 
and prednisolone.7 21 22 In the past decade, bortezomib, an 
anti-angiogenic agent has emerged as a promising treatment for 
MM.23 24 Recent reports have mentioned the efficacy of borte-
zomib for EMP or MM with plasmacytomas.25–28
Long-term survival in PPP remains unclear. Koss et al reported 
tumour dissemination to regional or distant lymph nodes, in a 
manner similar to lung carcinomas along with a 20% rate of 
progression to MM.5 In a recent literature review by Edelstein 
et al, a 40% rate of progression to MM was noted, necessitating 
serial quantification of M-protein after treatment of PPP.7
learning points
 ► The presentation of primary pulmonary plasmacytoma (PPP) 
with IgG lambda monoclonal gammopathy is a rare and an 
unprecedented finding.
 ► PPP lacks specific clinical and radiographic features and 
therefore differentiating it from other, more common causes 
of lung masses, for example, primary lung cancer and rarely 
primary extranodal lymphoma and primary pulmonary 
sarcomas is prudent.
 ► Transthoracic needle aspiration or needle/core biopsy 
represent safe, effective and accurate modalities for 
diagnosing lung malignancies. They are becoming a strong 
alternative to surgical intervention.
 ► In general, anatomic pulmonary resection is the best 
treatment of PPP, while chemotherapy with or without 
radiotherapy may be a better choice in those with diffuse 
pulmonary involvement or widespread metastasis.
 ► Bortezomib represents a promising agent for extramedullary 
plasmacytoma or multiple myeloma with multiple 
plasmacytomas.
 ► Accrual of a large number of similar cases is needed in order 
to establish a standard therapeutic approach towards this 
condition.
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